Table 3. Comparison of biological and clinical variables of the Italian and French cohorts of CD16+/CD56- CD8+ T-LGL leukemia patients.

Variable	CD16+/CD56- CD8+ T-LGL leukemia patients (Padua, Italy) n = 41	CD16+/CD56- CD8+ T-LGL leukemia patients (Rennes, France) n = 20
Gender
Males	15 (37%)	7 (35%)
Females	26 (63%)	13 (65%)
STAT3 mutation	37 (90%)	17 (85%)
Neutropenia (ANC < 1,500)	37 (90%)	18 (90%)
Severe neutropenia (ANC < 500)	17 (41%)	2 (10%)

ANC, absolute neutrophil count.